On April 23, Biocon board approved the raising of funds up to Rs 4,500 crore via the issuance of equity shares, ...

Pharma stocks Zydus Life, Aurobindo Pharma and Biocon gained up to nearly 3% in trade after they secured regulatory approvals ...

Biocon Biologics Ltd today announced that the CHMP of the European Medicines Agency has issued positive opinions recommending ...

Denosumab plus romosozumab vs denosumab only was associated with improved bone mineral density among patients with severe ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event, suggested an observational trial weighted to emulate a clinical trial.

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

Biosimilar denosumab of Alkem (Denuril) showed comparable efficacy, safety, pharmacokinetics, pharmacodynamics, and ...

The US Food and Drug Administration (FDA) has approved denosumab-bnht (Conexxence/Bomyntra), manufactured by Fresenius Kabi, for all indications of the reference ...

Please provide your email address to receive an email when new articles are posted on . Denosumab-bnht was approved as medication referencing Amgen’s Prolia and Xgeva. A settlement between Amgen ...

Biocon Biologics Ltd receives positive CHMP opinions for denosumab biosimilars Vevzuo and Denosumab BBL, advancing bone ...